Similarly, prior to the discovery of the senolytic properties of the HSP90 inhibitor 17-DMAG (alvespimycin) [86], it had been demonstrated that 17-DMAG reduced atherosclerosis in the Apo-E knock-out model, although it was originally assigned to be a result of NF-κB and STAT signalling pathway suppression [87]. Here, APOE is linked to atherosclerosis.